Pozdravljeni,
Če prav razumem, vi predlagate, da se ljudem ki imajo hude rezistentne oblike depresije, ne predpisujejo antipsihotiki ker lahko provzročajo hude stranske učinke in so samo "lahko učinkoviti"?
Vaše razmišljanje je na prvi pogled logično, ampak tudi precej surovo, saj bi to pomenilo, da pustimo ljudi trpeti in propadati, zato ker ne moremo zagotoviti 100% učinkovitosti in varnosti.
Če to prenesemo v druge medicinske specialnosti, bi to pomenilo, da bi večino resno bolnih pustili umreti, saj nimamo dovolj varnih in učinkovitih zdravil za številne bolezni, imamo pa zdravila ki lahko pomagajo in imajo resne stranske učinke. Seveda, zdravljenje lahko tudi odklonimo, nas nobeden ne sili, da jemljemo zdravila, če tega ne želimo (razen v primerih ki so predpisani v Zakonu o duševnem zdravju).
Vi imate pravico do svojega mnenja, in imate tudi pravico ne jemati zdravila za katera menite, da provzročajo več škode kot koristi. Moje mnenje je da, je izguba življenja največja škoda, in končna, brez možnosti popravka. V tej luči moramo gledati na možnosti zdravljenja, ki so še daleč od tega, da bi bile zadovoljive, ampak s tem, zaenkrat, razpolagamo in to lahko uporabljamo, ali ne uporabljamo.
Reviews and Overviews
Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials
J. Craig Nelson , M.D.; George I. Papakostas , M.D.
Abstract
Objective: The authors sought to determine by meta-analysis the efficacy and tolerability of adjunctive atypical antipsychotic agents in major depressive disorder. Method: Searches were conducted of MEDLINE/PubMed (1966 to January 2009), the Cochrane database, abstracts of major psychiatric meetings since 2000, and online trial registries. Manufacturers of atypical antipsychotic agents without online registries were contacted. Trials selected were acute-phase, parallel-group, double-blind controlled trials with random assignment to adjunctive atypical antipsychotic or placebo. Patients had nonpsychotic unipolar major depressive disorder that was resistant to prior antidepressant treatment. Response, remission, and discontinuation rates were either reported or obtained. Data were extracted by one author and checked by the second. Data included study design, number of patients, patient characteristics, methods of establishing treatment resistance, drug doses, duration of the adjunctive trial, depression scale used, response and remission rates, and discontinuation rates for any reason or for adverse events. Results: Sixteen trials with 3,480 patients were pooled using a fixed-effects meta-analysis. Adjunctive atypical antipsychotics were significantly more effective than placebo (response: odds ratio=1.69, 95% CI=1.46–1.95, z=7.00, N=16, p<0.00001; remission: odds ratio=2.00, 95% CI=1.69–2.37, z=8.03, N=16, p<0.00001). Mean odds ratios did not differ among the atypical agents and were not affected by trial duration or method of establishing treatment resistance. Discontinuation rates for adverse events were higher for atypical agents than for placebo (odds ratio=3.91, 95% CI=2.68–5.72, z=7.05, N=15, p<0.00001). Conclusions: Atypical antipsychotics are effective augmentation agents in major depressive disorder but are associated with an increased risk of discontinuation due to adverse events.
Lep pozdrav,
Če prav razumem, vi predlagate, da se ljudem ki imajo hude rezistentne oblike depresije, ne predpisujejo antipsihotiki ker lahko provzročajo hude stranske učinke in so samo "lahko učinkoviti"?
Vaše razmišljanje je na prvi pogled logično, ampak tudi precej surovo, saj bi to pomenilo, da pustimo ljudi trpeti in propadati, zato ker ne moremo zagotoviti 100% učinkovitosti in varnosti.
Če to prenesemo v druge medicinske specialnosti, bi to pomenilo, da bi večino resno bolnih pustili umreti, saj nimamo dovolj varnih in učinkovitih zdravil za številne bolezni, imamo pa zdravila ki lahko pomagajo in imajo resne stranske učinke. Seveda, zdravljenje lahko tudi odklonimo, nas nobeden ne sili, da jemljemo zdravila, če tega ne želimo (razen v primerih ki so predpisani v Zakonu o duševnem zdravju).
Vi imate pravico do svojega mnenja, in imate tudi pravico ne jemati zdravila za katera menite, da provzročajo več škode kot koristi. Moje mnenje je da, je izguba življenja največja škoda, in končna, brez možnosti popravka. V tej luči moramo gledati na možnosti zdravljenja, ki so še daleč od tega, da bi bile zadovoljive, ampak s tem, zaenkrat, razpolagamo in to lahko uporabljamo, ali ne uporabljamo.
Reviews and Overviews
Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials
J. Craig Nelson , M.D.; George I. Papakostas , M.D.
Abstract
Objective: The authors sought to determine by meta-analysis the efficacy and tolerability of adjunctive atypical antipsychotic agents in major depressive disorder. Method: Searches were conducted of MEDLINE/PubMed (1966 to January 2009), the Cochrane database, abstracts of major psychiatric meetings since 2000, and online trial registries. Manufacturers of atypical antipsychotic agents without online registries were contacted. Trials selected were acute-phase, parallel-group, double-blind controlled trials with random assignment to adjunctive atypical antipsychotic or placebo. Patients had nonpsychotic unipolar major depressive disorder that was resistant to prior antidepressant treatment. Response, remission, and discontinuation rates were either reported or obtained. Data were extracted by one author and checked by the second. Data included study design, number of patients, patient characteristics, methods of establishing treatment resistance, drug doses, duration of the adjunctive trial, depression scale used, response and remission rates, and discontinuation rates for any reason or for adverse events. Results: Sixteen trials with 3,480 patients were pooled using a fixed-effects meta-analysis. Adjunctive atypical antipsychotics were significantly more effective than placebo (response: odds ratio=1.69, 95% CI=1.46–1.95, z=7.00, N=16, p<0.00001; remission: odds ratio=2.00, 95% CI=1.69–2.37, z=8.03, N=16, p<0.00001). Mean odds ratios did not differ among the atypical agents and were not affected by trial duration or method of establishing treatment resistance. Discontinuation rates for adverse events were higher for atypical agents than for placebo (odds ratio=3.91, 95% CI=2.68–5.72, z=7.05, N=15, p<0.00001). Conclusions: Atypical antipsychotics are effective augmentation agents in major depressive disorder but are associated with an increased risk of discontinuation due to adverse events.
Lep pozdrav,
